BOC-GROUP
15.1.2020 15:29:10 CET | Business Wire | Press release
BOC Group , a global leader in enterprise business process analysis software (EBPA), and TIM Solutions , a leading provider of business process management (BPM) software for low-code human workflow automation, announced their strategic partnership today, focused on delivering accelerated digitalization of Business Process Automation at the enterprise level.
Both BOC Group and TIM have experienced that rapid automation of an existing manual process is the key first step in successful delivery of process automation. Once the automation is up-and-running, process analysis and design ensure that the process is quickly optimized further to reach cost reduction efficiencies of up-to 80%. What’s more, this approach delivers on all key targets of automation – reduction of redundant process activities, digitalization of manual tasks, and the overall improvement of customer experience. By combining TIM’s process automation with ADONIS’ process design and analysis capabilities, organizations can expect both a shorter time-to-value when automating processes, and a higher value-add delivered by the optimally designed automation.
The past months of collaboration between TIM and BOC Group have culminated today in a meeting of both management teams at BOC Group’s headquarters in Vienna, Austria, where the release of the ADONIS Process Automation module on the BOC Marketplace was announced. Customers of both partners can now benefit from this native integration that combines the intuitive process design, analysis and simulation of ADONIS with the seamless deployment, automation and monitoring of business processes in TIM’s process automation platform.
“Our customers seek to use low-code process automation as a key step in their digital journey. TIM is uniquely positioned as a simple, powerful and cost-effective automation platform that allows our customers to turn their process designs into automated workflows” mentioned Dr. Harald Kühn, BOC Group Board member. “We are excited about ADONIS Process Automation, powered by TIM, going live today on the BOC Marketplace” added Dr. Kühn.
“Having an optimal process design is a key success factor in rolling-out an automated human workflow. We are certain that the process analysis and design capabilities of ADONIS will be greatly beneficial when designing and optimizing automated workflows.” said TIM Solutions CEO, Mr. Hermann Filss “We are excited to be partnering with BOC Group as we look to directly profit from their global client footprint and rapidly spread the use of TIM around the world,” added Mr. Filss.
Both vendors have kicked-off campaigns to roll-out the integration as they look to capture a very active process automation market with their unique combined offering. Interested parties are welcome to schedule a Proof of Concept through the BOC Marketplace .
About BOC Group
BOC is a global leader in Enterprise Modelling Software across the Enterprise Business Process Analysis (EBPA), Governance Risk and Compliance (GRC) and Enterprise Architecture (EA) domains. Enabling customers to successfully and continuously re-design their digital enterprise to ensure business success at every level of the organization.
ADONIS customers include:
- Allianz
- Comcast
- Emerson
- Hilti
- Telefonica
BOC delivers products and services globally to over 1,000 companies supported by over 90 partners around the globe.
About TIM Solutions
TIM Solutions is focused on developing a simple method for automating and managing human workflows. They provide comprehensive solutions and consulting to their customers in the field Business Process Automation and Business Process Management.
TIM customers include:
- BMW AG
- Deutsche Bahn AG
- ManpowerGroup
- E.ON SE
- Tata Consultancy Services
TIM BPM Suite is used by more than 310 companies in 56 countries around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom